Dr. Stanley Chaleff, MD | Scarborough ...

Dr. Stanley Chaleff, MD

Claim this profile

Maine Children's Cancer Program

Studies Brain Tumor
Studies Low Grade Glioma
6 reported clinical trials
14 drugs studied

Area of expertise

1

Brain Tumor

Stanley Chaleff, MD has run 4 trials for Brain Tumor. Some of their research focus areas include:

NTRK positive
Stage IV
ALK positive
2

Low Grade Glioma

Stanley Chaleff, MD has run 3 trials for Low Grade Glioma. Some of their research focus areas include:

Stage IV
BRAF negative
Stage I

Affiliated Hospitals

Image of trial facility.

Maine Children's Cancer Program

Clinical Trials Stanley Chaleff, MD is currently running

Image of trial facility.

Selumetinib vs. Chemotherapy

for Brain Cancer

This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.

Recruiting

2 awards

Phase 3

Image of trial facility.

Chemotherapy + Radiation Therapy

for Brain Cancer

This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to other parts of the brain or body (localized). This study has 2 goals: 1) optimizing radiation for patients who respond well to induction chemotherapy to diminish spinal cord relapses, 2) utilizing higher dose chemotherapy followed by conventional RT in patients who did not respond to induction chemotherapy. Chemotherapy drugs, such as carboplatin, etoposide, ifosfamide, and thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays or high-energy protons to kill tumor cells and shrink tumors. Studies have shown that patients with newly-diagnosed localized NGGCT, whose disease responds well to chemotherapy before receiving radiation therapy, are more likely to be free of the disease for a longer time than are patients for whom the chemotherapy does not efficiently eliminate or reduce the size of the tumor. The purpose of this study is to see how well the tumors respond to induction chemotherapy to decide what treatment to give next. Some patients will be given RT to the spine and a portion of the brain. Others will be given high dose chemotherapy and a stem cell transplant before RT to the whole brain and spine. Giving treatment based on the response to induction chemotherapy may lower the side effects of radiation in some patients and adjust the therapy to a more efficient one for other patients with localized NGGCT.

Recruiting

1 award

Phase 2

More about Stanley Chaleff, MD

Clinical Trial Related

6 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Stanley Chaleff, MD has experience with

  • Selumetinib
  • Repotrectinib
  • Carboplatin; Vincristine Sulfate
  • Carboplatin; Vincristine
  • Selumetinib Sulfate
  • Vinblastine Sulfate

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Stanley Chaleff, MD specialize in?

Is Stanley Chaleff, MD currently recruiting for clinical trials?

Are there any treatments that Stanley Chaleff, MD has studied deeply?

What is the best way to schedule an appointment with Stanley Chaleff, MD?

What is the office address of Stanley Chaleff, MD?

Is there any support for travel costs?